Skip to main content
. Author manuscript; available in PMC: 2009 Sep 4.
Published in final edited form as: Prostate. 2009 Jan 1;69(1):82–91. doi: 10.1002/pros.20857

Fig. 7.

Fig. 7

Antitumor activity of MV-CEA administered IT in a subcutaneous PC-3 prostate cancer model. Eleven days after tumor implantation the mice were treated with either MV-CEA administered IT at a total dose of 6 ×106 TCID50 (n = 10) or UV-inactivated MV-CEA (n = 10). A: The mice had similar tumor volumes before treatment (P = 0.326). There was significant suppression of tumor growth in MV-CEA-treated animals (P = 0.004 at day 24). The plot was censored at 24 days because of deaths occurring in the UV-inactivated control group. B: Mice treated with MV-CEA had significantly longer survival compared to the UV-inactivated controls (P = 0.001).